Retrophin Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Retrophin (RTRX) Tops Q3 EPS Views
November 7, 2017 4:38 PM ESTRetrophin (NASDAQ: RTRX) reported Q3 EPS of $0.15, $0.40 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $40.3 million versus the consensus estimate of $40.51 million.
-- The Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase- associated neurodegeneration (PKAN) remains... More